The Motley Fool··Prosper Junior BakinyRecursion Pharma Hits 52-Week Low: AI Biotech's Promise Meets Pipeline Reality
AI-focused biotech Recursion Pharmaceuticals hits 52-week low lacking FDA approvals. Early-stage pipeline and unproven clinical data make stock highly speculative despite partnerships and Nvidia backing.
NVDASNYRHHBYBAYRYRXRXstock valuationbiotech